Evidence map›Paper›PMID 38806595›Full record

ArticleScientific reports2024

Clear surgical margins as a prognostic indicator for disease recurrence, with no impact on survival rates in patients with myxofibrosarcoma.

Tomáš Tomáš, Vasileios Apostolopoulos, Lukáš Pazourek, Marián Kubíček, Iva Staniczková Zambo, Dagmar Adámková, Pavel Šlampa, Michal Mahdal

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tomáš Tomáš *First Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200, Brno, Czech Republic.
Vasileios Apostolopoulos *First Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200, Brno, Czech Republic.
Lukáš PazourekFirst Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200, Brno, Czech Republic.
Marián KubíčekFirst Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200, Brno, Czech Republic.
Iva Staniczková ZamboFaculty of Medicine, Masaryk University, 62500, Brno, Czech Republic.
Dagmar AdámkováFaculty of Medicine, Masaryk University, 62500, Brno, Czech Republic.
Pavel ŠlampaFaculty of Medicine, Masaryk University, 62500, Brno, Czech Republic.
Michal MahdalFirst Department of Orthopaedic Surgery, St. Anne's University Hospital, 60200, Brno, Czech Republic. michal.mahdal@fnusa.cz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myxofibrosarcoma presents an infiltrating growth pattern that results in a high tendency for local recurrence. Clear margin resection is challenging because of microscopic infiltration. The purpose of the present study was to analyze the overall and disease-free survival rates of patients with myxofibrosarcoma and the prognostic factors that determine both survival and disease recurrence. Among the 111 patients included in our study, the 5-year overall survival rate was 65.5%. An age of more than 65 years (hazard ratio [HR] 1.9 [95% confidence interval (CI) 1.4-5.6]; p < 0.001), a tumor size of more than 5 cm (HR 2.8 [95% CI 0.9-8.1]; p = 0.049) and the G3 tumor grade (HR 14.1 [95% CI 2.1-105.0]; p < 0.001) negatively affected overall survival. The 5-year recurrence-free survival rate was 49.4%. R1/R2-type resection (HR 2.4 [95% CI 1.0-5.6]; p = 0.048) had a detrimental effect on tumor recurrence. Clear margins had a positive impact on recurrence-free survival, but did not significantly affect overall patient survival, suggesting that other factors may play a more significant role in determining patient outcomes. A surgical margin of 2 mm was not sufficient to significantly influence the incidence of recurrence. Consequently, a wider surgical margin may be necessary to reduce the risk of myxofibrosarcoma recurrence.

Indexed as

FibrosarcomaMargins of ExcisionNeoplasm Recurrence, LocalAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival Rate

Identifiers

PMID38806595
PMCPMC11133331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.